Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Esperion logo — Creative execution for today and life-saving innovation for...

Esperion

Creative execution for today and life-saving innovation for tomorrow

Founded 2008 United States Ann Arbor, United States 339 employees Post-IPO Equity Total: $852.55M Biotechnology, Health Care +1

General Information

Company Name Esperion
Founded Year 2008
Location United States Ann Arbor, United States
Founders / Decision Makers
Team member
Employees 339
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Esperion. To contact Esperion, visit esperion.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Esperion compare?

A PDF of Esperion and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Esperion soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Esperion

Esperion is an innovative biotechnology and pharmaceutical startup that is singularly focused on disrupting high cholesterol to improve overall health. Founded in 1998 and headquartered in the United States, Esperion is committed to lipid management for everybody, striving to make its medicines accessible and affordable. The company's entrepreneurial team of industry leaders is inclusive, passionate, and resourceful, reflecting its dedication to making a difference in the healthcare sector. Esperion recently secured a significant $97.80M Post-IPO Equity investment on 18 January 2024, signifying the confidence of investors in the company's mission and potential. Despite the absence of specific information regarding the investors of this substantial investment, it is evident that Esperion's innovative approach to addressing unmet needs in cholesterol management has captured the attention and support of the investment community. As a startup operating at the intersection of biotechnology, healthcare, and pharmaceuticals, Esperion's focus on developing and commercializing innovative medicines and combinations to lower cholesterol, particularly for patients with unmet needs, positions it well for potential growth and impact in the industry. With a strong emphasis on disrupting the status quo in cholesterol management, Esperion's future prospects and potential for making a meaningful difference in healthcare are worth monitoring closely. For more information, please visit esperion.com and follow the company on Twitter at www.twitter.com/EsperionInc.

Business keywords: pharmaceutical company, drug discovery, cardiovascular diseases, metabolic diseases, high cholesterol, lipid management, HDL therapy, small molecule drugs, LDL-C, statins, innovative medicines, entrepreneurial team, patient-centric approach

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $97.80M -
18 Jan 2024
Post IPO Equity $225.00M -
02 Dec 2021
Post IPO Equity $50.00M 1
Oberland Capital
Oberland Capital
26 Apr 2021
Post IPO Equity $142.50M -
08 Aug 2017
Post IPO Equity $189.90M -
24 Mar 2015
Post IPO Equity $91.60M -
14 Oct 2014
Venture Round $33.00M 6
Asset Management Ventures Arboretum Ventures Longitude Capital
Asset Management Ventures, Arboretum Ventures +4
25 Apr 2013
Series A $22.75M 4
Arboretum Ventures Alta Partners Domain Associates
Arboretum Ventures, Alta Partners +2
30 Apr 2008

Esperion Alternatives & Competitors

View All Alternatives
Esperion vs
Amira Pharmaceuticals
Amira Pharmaceuticals

Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early...

Series B
15 employees
Biotechnology, Health Care
Compare Esperion vs Amira Pharmaceuticals
Esperion vs
BeBetter Med
BeBetter Med China

Clinical-stage drug discovery and development of advanced novel medicines for cancer and other sever...

Private Equity
5 employees
Health Care, Pharmaceutical
Compare Esperion vs BeBetter Med
Esperion vs
Cyrus Therapeutics
Cyrus Therapeutics Korea South

Drugging the undruggable targets

Series B
15 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Esperion

Creative execution for today and life-saving innovation for tomorrow
Esperion was founded in 2008.
Esperion is headquartered in Ann Arbor, United States.
Esperion operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on pharmaceutical company, drug discovery, cardiovascular diseases and metabolic diseases.
Esperion has approximately 339 employees.
Esperion has completed 8 funding rounds, raising a total of $852.55M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Esperion include Amira Pharmaceuticals, BeBetter Med, Cyrus Therapeutics, Septerna, Jnana Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Esperion and Amira Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Esperion, https://bouncewatch.com/company/esperion, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout